Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential to driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment.  To support the discovery of novel CDK2 inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and …Read More >

Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability.  To support the discovery of potent and selective WRN inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to support hit finding and lead optimization efforts targeting WRN.  Our panel of services also include high-quality WRN protein production …Read More >

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >

WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors show that LX-039 exhibits potent activity in ER degradation and proliferation assays. With favorable ADME/PK properties, LX-039 also exhibits higher efficacy in a tamoxifen-resistant MCF7 CDX model compared to fulvestrant, with up to 90% inhibition …Read More >

WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs).  Our comprehensive platform includes cell line selection and target expression, assessment of binding affinity (SPR, flow cytometry), in vitro activity testing (T cell activation, cytokine release, cytotoxicity), and evaluation of in vivo efficacy (using HSC and PBMC …Read More >

WuXi AppTec scientists recently contributed to a research study which utilized an affinity purification mass spectrometry approach to identify nuclear interacting partners of Transcriptional Enhanced Associate Domain (TEAD) proteins.  The authors found a significant enrichment of interacting proteins linked to DNA damage, and they showed that depletion of TEAD transcription factors makes cells more susceptible …Read More >

We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics.  An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model. Check out our …Read More >

Offering a wide range of targeted oncology services and translational models.  Our comprehensive platform includes: in vitro biochemical, biophysical, and cell-based assays, including 600+ human cancer cell lines 70+ PDX-derived cell lines SPR, HTRF, ELISA, and FRET techniques ex vivo PD analysis, including: histopathology services NGS Flow cytometry Gene/protein expression analysis in vivo tumor models, …Read More >

Comprehensive cell line screening assays integrated with downstream pharmacological services Cell panel  of 600+ human cancer cell lines for single agent or combinatory drug screening, covering 30+ cancer types 100+ mouse cell lines, across 20+ cancer types 95 PDX-derived cell lines 320+ CDX models, ready for use 1,400+ PDX models, for primary tumor cell line …Read More >